Camille Jackson, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1700046943
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (35.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Intuitive Surgical at 41.7% of the total. Reporting peaked in 2024 at $10,939 and has fallen 63.4% since, to $4,002 in 2025.
Across 182 payments — averaging $192.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$15K
- GSK$7K
- Pfizer$4K
- Clovis Oncology, Inc.$3K
- AstraZeneca$2K
- Eisai Inc.$2K
- plus $2K from 33 others
Across 66 payments — averaging $12,895 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$318K
- Genentech, Inc.$267K
- Tesaro, Inc.$174K
- GSK$49K
- EMD Serono, Inc.$20K
- Seagen Inc.$15K
- plus $9K from 1 others
What the payments were for
- Consulting fees$11,31032%
- Speaking & faculty fees$5,12515%
- Travel & lodging$2,1486%
- Food & beverage$4,03412%
- Education$12,37135%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $14,583 |
| GSK | 28 | $7,145 |
| Pfizer | 6 | $4,224 |
| Clovis Oncology, Inc. | 11 | $2,864 |
| AstraZeneca(2 entities) | 21 | $2,320 |
| Eisai Inc. | 13 | $1,628 |
| Medtronic | 6 | $357 |
| Merck | 11 | $270 |
| Myriad Genetic Laboratories, Inc. | 10 | $232 |
| Genmab U.S., Inc. | 6 | $134 |
| Novartis | 7 | $125 |
| AbbVie | 7 | $121 |
| Caris MPI, Inc. | 1 | $94 |
| Conmed Corporation | 1 | $83 |
| Mirati Therapeutics, Inc. | 4 | $82 |
| Johnson & Johnson | 3 | $61 |
| Amgen | 3 | $60 |
| Incyte Corporation | 3 | $53 |
| EMD Serono, Inc. | 3 | $51 |
| Seagen Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Integra Lifesciences Corporation | 1 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Tempus AI, Inc | 1 | $29 |
| Kerecis Limited | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Immunogen, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Sobi, Inc | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Emmaus Medical, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,988 in reported general payments places this provider in the 85th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 20 | $1,021 |
| Estradiol | 25 | $649 |
| Megestrol Acetate | 27 | $542 |
| Clindamycin Phosphate | 13 | $373 |
| Oxycodone Hcl | 82 | $297 |
| Fluconazole | 21 | $252 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $120 |
| Metronidazole | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$97K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Elizabeth EvansOklahoma City$3K
- Lauren DockeryOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
- Aleia CrimOklahoma City$862
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.